Value through Innovation16 April 2014

Boehringer Ingelheim in Japan - Efficient new structure

On 1 October 2010, Boehringer Ingelheim Japan, Inc. was established as a holding company and provides the support functions for the three business areas, Prescription Medicines, Consumer Health Care and Animal Health as well as for Operations. The goal is to raise the value and efficiency of the business areas.

On 1 April 2011, Boehringer Ingelheim Japan announced that it reorganised its corporate group to improve the efficiency and productivity of its companies in Japan.

Under the new structure, Boehringer Ingelheim Japan, Inc. is able to offer higher quality services and support to enable its four whollyowned subsidiaries – Nippon Boehringer Ingelheim Co., Ltd., SSP Co., Ltd., Boehringer Ingelheim Vetmedica Japan Co., Ltd. and Boehringer Ingelheim Seiyaku – to achieve their strategic goals.

Boehringer Ingelheim Japan, Inc.
The company Boehringer Ingelheim Japan, Inc., located in Tokyo’s Shinagawa-ku district, was established on 1 October 2010. The support functions (Human Resources, Finance, Procurement, Information Systems, Legal and Communications) are consolidated in Boehringer Ingelheim Japan, Inc. These respect the particular qualities of each company and provide services to increase value for customers in their respective markets. Company employees number 188 (1 April 2011).

Nippon Boehringer Ingelheim Co. Ltd.
The Japanese subsidiary Nippon Boehringer Ingelheim Co. Ltd., based in Shinagawa-ku, was established on 30 June 1961 and this year celebrates its 50th anniversary. The company’s net sales for the fiscal year to 31 December 2010 amounted to JPY 162.1 billion. The company, which has 1,767 employees (1 April 2011), is engaged in the research and development, import, manufacture and marketing of pharmaceuticals as well as importing and exporting and marketing pharmaceutical active ingredients and intermediates.

The four Nippon Boehringer Ingelheim products with the largest sales in 2010 are the Micardis® family (JPY 81.8 billion on an NHI price basis), Alesion® (JPY 25.6 billion), Spiriva® (JPY 18.6 billion) and BI-Sifrol® (JPY 14.3 billion). More than a half of its mainstays are expected to grow above the market growth rate in 2011.

Although the antihypertensive market will grow by 3.0 %, NBI’s Micardis® family is expected to grow by 4.0 %. The growth rate of Spiriva®, 15.9 %, will significantly surpass the 5.1 % of the total COPD treatment market. BI-Sifrol® will grow by 6.6 %, thereby exceeding the 3.9 % growth of the total Parkinson’s disease medicine market.

SSP Co. ,Ltd.
The consumer healthcare products- focused company SSP Co. ,Ltd., founded and established in 1765 and 1927 and located in Tokyo’s Chuo-ku district, was acquired by Boehringer Ingelheim in 2010. The company’s net sales amounted to JPY 35.2 billion in the fiscal year ending 31 December 2010.

The company has a total of 755 employees ( 1 April 2011) and undertakes the manufacture and marketing of over-the-counter (OTC) drugs, other healthcare products and medical devices. The company’s core products are S.CUP, nutritional supplement, HYTHIOL for skin care, EVE for headache, fever and menstrual cramps, S.TAC for colds, SURULAC, a laxative, and GASTOL, an M1 blocker digestive medicine.

Boehringer Ingelheim Vetmedica Japan
Boehringer Ingelheim Vetmedica Japan was founded on 5 February 2002 and is based in Tokyo’s Shinagawa-ku district. The company specialises in the development, import and marketing of veterinary medicines. In the fiscal year ending 31 December 2010, Boehringer Ingelheim Vetmedica Japan achieved a turnover of JPY 4.2 billion. The company has 38 employees (1 April 2011).
Its main products include Ingelvac® CircoFLEX, Metacam® Injection 2 % (meloxicam) and Vetmedin®.

Boehringer Ingelheim Seiyaku based in Higashine, Yamagata Prefecture, specialises in the manufacture of pharmaceutical products. The company has 184 employees (1 April 2011) and was established in February 1947. Net sales for the fiscal year ending 31 December 2010 amounted to JPY 56.0 billion.

Research and development
The Kobe Pharma Research Institute (KPRI) in Kobe, Hyogo Prefecture, plays an important role in supporting international R&D activities, in the search for new drug targets in Japan and in the production of early medicine formulations, as well as undertaking specific pharmacokinetic studies as a support centre for Boehringer Ingelheim’s global R&D activities.